"Acetates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivatives of ACETIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxymethane structure.
| Descriptor ID |
D000085
|
| MeSH Number(s) |
D02.241.081.018 D10.251.400.045
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Acetates".
Below are MeSH descriptors whose meaning is more specific than "Acetates".
This graph shows the total number of publications written about "Acetates" by people in this website by year, and whether "Acetates" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
| 1998 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2008 | 0 | 3 | 3 |
| 2009 | 1 | 2 | 3 |
| 2010 | 2 | 1 | 3 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 3 | 1 | 4 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 3 | 3 |
| 2023 | 1 | 3 | 4 |
| 2024 | 4 | 1 | 5 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Acetates" by people in Profiles.
-
Reduction of Vancomycin-Associated Acute Kidney Injury With Montelukast. J Infect Dis. 2025 Jul 30; 232(1):191-198.
-
Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical Trial. JAMA Netw Open. 2024 10 01; 7(10):e2439332.
-
Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant. Transplant Cell Ther. 2024 12; 30(12):1193.e1-1193.e8.
-
Montelukast as a repurposable additive drug for standard-efficacy multiple sclerosis treatment: Emulating clinical trials with retrospective administrative health claims data. Mult Scler. 2024 May; 30(6):696-706.
-
Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients. J Pediatric Infect Dis Soc. 2024 Feb 28; 13(Supplement_1):S14-S21.
-
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis. N Engl J Med. 2024 02 29; 390(9):783-794.
-
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis. Aliment Pharmacol Ther. 2024 01; 59(2):186-200.
-
Lessons Learned From the First-In-Human Compassionate Use of Connect-EA? in Ten Patients With Esophageal Atresia. J Pediatr Surg. 2024 Mar; 59(3):437-444.
-
Monitoring the treatment of urea cycle disorders using phenylbutyrate metabolite analyses: Still many lessons to learn. Mol Genet Metab. 2023 11; 140(3):107699.
-
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study. Hepatology. 2023 08 01; 78(2):397-415.